The evolution of drug-resistant viral strains and anatomical and cellular reservoirs of HIV
pose significant clinical challenges to antiretroviral therapy. CCR5 is a coreceptor critical for …

Hematopoietic stem-cell (HSC) transplantation using a donor with a homozygous mutation
in the HIV co-receptor CCR5 (CCR5Δ32/Δ32) holds great promise as a cure for HIV-1 …

Transplanting HIV-1 positive patients with hematopoietic stem cells homozygous for a 32 bp
deletion in the chemokine receptor type 5 (CCR5) gene resulted in a loss of detectable HIV …

Human immunodeficiency virus (HIV) infection can be controlled by anti-retroviral therapy.
Suppressing viral replication relies on life-long medication, but anti-retroviral therapy is not …

Transplantation of hematopoietic stem cells (HSCs) with a naturally occurring CCR5
mutation confers a loss of detectable HIV-1 in the patient, making ablation of the CCR5 gene …

Globally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for
which successful therapeutic options are still being investigated. Challenges facing current …

Cell therapy efforts for treating HIV+ patients are challenged by limited availability of donors
with naturally occurring CCR5 mutations conferring resistance. Xu et al.(2019) report a …

CC chemokine receptor type 5 (CCR5) is the main co-receptor for HIV entry into the target
CD4+ cells, and homozygous CCR5Δ32/Δ32 cells are resistant to CCR5-tropic HIV …

Allogeneic hematopoietic stem and progenitor cell transplant (HSCT) of CCR5 null
(CCR5Δ32) cells can be curative for HIV-1-infected patients. However, because allogeneic …

CCR5 serves as an essential coreceptor for human immunodeficiency virus type 1 (HIV-1)
entry, and individuals with a CCR5Δ32 variant appear to be healthy, making CCR5 an …